EU officials clash with Chinese firm on drug factory inspection

London – European medicines regulators have issued a notice that an ingredient for a generic brain cancer drug made in China does not meet manufacturing standards, after inspectors were refused entry to a factory run by Jiangsu Yew Pharmaceutical Co. Ltd.

The incident, reported in a published this week on a database maintained by the European Medicines Agency, is the latest example of regulatory problems with bulk pharmaceutical substances manufactured in China.

It follows a scandal over tainted supplies of the widely used heart drug valsartan from Zhejiang Huahai Pharmaceutical, which led to dozens of recalls around the world of finished tablets containing the Chinese product. U.S. officials have also recently recalled porcine thyroid active ingredient from China due to inconsistent quality.

In the latest case, Jiangsu Yew refused to allow a site inspection by Hungarian officials, acting on behalf of Europe’s drug regulatory system. The rebuttal led the EU authorities to determine that its supplies of temozolomide, used to treat brain tumors, did not comply with good manufacturing standards.

The company’s export director Henry Yang told Reuters via email that the inspection was refused because Jiangsu Yew only made an intermediate product, rather than an active pharmaceutical ingredient (API), so an audit was not required.

Manufacturers in China and India supply more than two-thirds of all bulk pharmaceutical substances used in medicines, industry executives estimate, with China accounting for the lion’s share.

In recent years, U.S. and European regulators have increased scrutiny of Asian drug factories following the adulteration of the blood thinner heparin, which sickened hundreds and caused the deaths of at least 81 Americans in 2007 and 2008.

"Monitoring Desk"

RELATED POSTS

246
Pakistan-Indonesia trade relations will expand in future: RCCI
CIIE highly successful in boosting trade with Pakistan, says China
Pakistan to hold policy-level talks with IMF this week
CPEC: Wind, solar energy production to double by 2022
PTI govt likely to decrease profit margins for power plant owners
Sindh Engro seeks reduction in returns on energy projects
Private sector to be engaged in CPEC projects: Asad Umar
Govt gets Chinese loan for four CPEC projects
For CPEC, investors urge political unity
Pakistan needs to make CPEC an engine of innovation
Rules being finalised for Naya Pakistan Housing project
Tajikistan keen in promoting trade with Pakistan
Pakistan and China in talks to finalise co-operation modalities
Pakistan, China can play vital role in regional progress
‘Pakistan will learn from China’: Imran Khan on anti-poverty plan

FOLLOW US


About Corridor.pk

Corridor.pk is Pakistan’s leading regional connectivity media & communication/outreach platform, dedicated to profiling and promoting the business activities, news and views on the regionally connected business corridor across OBOR. 

     

Addional Information

 Ethics Policy     Advertise
 Terms & Conditions
 Contact Us